Sapienza University Of Rome
- Address
- lock Available on a paid plan
Neurosciences and Neurodegenerative Research
At Sapienza University Of Rome, clinical trials in nervous system diseases focus on conditions such as multiple sclerosis, Alzheimer’s disease, dementia, and broader neurodegenerative disorders. This research is designed to better understand disease activity, assess treatment effects, and improve care for people living with complex brain and nervous system conditions.
- Studies in relapsing forms of multiple sclerosis examining whether new approaches can help control central nervous system inflammation
- Research in Alzheimer’s disease aimed at evaluating potential ways to reduce brain-related complications and support cognitive health
- Trials across neurocognitive disorders and related brain diseases seeking better understanding of treatment benefit and disease progression
The site’s work in Neuroscienze Umane reflects a strong interest in both treatment evaluation and the search for more effective strategies in neurological and cognitive disorders.
Oncology and Prostate Cancer Studies
The research portfolio also includes neoplasms, with a clear emphasis on prostate cancer. These trials explore ways to strengthen treatment effectiveness for men with advanced or metastatic disease, combining standard cancer therapy with additional targeted approaches to improve outcomes.
- Studies in hormone-sensitive prostate carcinoma assessing whether adding focused radiotherapy can improve response to treatment
- Research in metastatic disease looking at better control of cancer spread and deeper biochemical response
- Trials evaluating the value of combining established systemic therapy with new local treatment strategies
This oncology work at the educational institution in Rome is centered on improving outcomes for patients with limited but spread-out cancer burden.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Sapienza University Of Rome
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| "APalutamide and stEReotactic body radiation therapy for low burden metastatic hormone senSItive prostate cancer, a rANdomized trial -PERSIAN". | Fondazione Radioterapia Oncologica Onlus | Phase II | Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| (R)-1-(Tert-Butyl)-N-(8-(2-((1-Methyl-1H-Pyrazol-4-Yl)Amino)Pyrimidin-4-Yl)-2-(Oxetan-3-Yl)-2,3,4,5-Tetrahydro-1H-Benzo[C]Azepin-5-Yl)-1H-1,2,3-Triazole-4-Carboxamide | 1 | Unknown | 2023-10-03 | 2023-10-03 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.